Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well axitinib works in treating patients with melanoma that
has spread to other places in the body or cannot be removed by surgery. Axitinib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborators:
National Cancer Institute (NCI) National Comprehensive Cancer Network